Predicting outcome in melanoma: where are we now?

Hdl Handle:
http://hdl.handle.net/10147/127496
Title:
Predicting outcome in melanoma: where are we now?
Authors:
Jennings, L; Murphy, G M
Affiliation:
Department of Dermatology, Beaumont Hospital, Beaumont, Dublin, Ireland. lorrainejenn@gmail.com
Citation:
Predicting outcome in melanoma: where are we now? 2009, 161 (3):496-503 Br. J. Dermatol.
Journal:
The British journal of dermatology
Issue Date:
Sep-2009
URI:
http://hdl.handle.net/10147/127496
DOI:
10.1111/j.1365-2133.2009.09324.x
PubMed ID:
19624540
Abstract:
Melanoma incidence continues to rise in most countries. This is of grave concern, given the mortality rate in a relatively young population. Current staging tools are limited in their ability to predict accurately those at risk of metastatic disease, relapse and treatment failure. This overview comprehensively reviews relevant literature, with the focus on the last 5 years, and discusses the current state of traditional and emerging novel methods of staging for melanoma and their effect on prognosis in this population.
Item Type:
Article
Language:
en
MeSH:
Adult; Early Detection of Cancer; Female; Humans; Lymphangiogenesis; Male; Melanoma; Middle Aged; Neoplasm Staging; Prognosis; Sentinel Lymph Node Biopsy; Skin Neoplasms; Tomography, Emission-Computed; Tumor Markers, Biological; Young Adult
ISSN:
1365-2133

Full metadata record

DC FieldValue Language
dc.contributor.authorJennings, Len
dc.contributor.authorMurphy, G Men
dc.date.accessioned2011-04-06T14:42:13Z-
dc.date.available2011-04-06T14:42:13Z-
dc.date.issued2009-09-
dc.identifier.citationPredicting outcome in melanoma: where are we now? 2009, 161 (3):496-503 Br. J. Dermatol.en
dc.identifier.issn1365-2133-
dc.identifier.pmid19624540-
dc.identifier.doi10.1111/j.1365-2133.2009.09324.x-
dc.identifier.urihttp://hdl.handle.net/10147/127496-
dc.description.abstractMelanoma incidence continues to rise in most countries. This is of grave concern, given the mortality rate in a relatively young population. Current staging tools are limited in their ability to predict accurately those at risk of metastatic disease, relapse and treatment failure. This overview comprehensively reviews relevant literature, with the focus on the last 5 years, and discusses the current state of traditional and emerging novel methods of staging for melanoma and their effect on prognosis in this population.-
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshEarly Detection of Cancer-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLymphangiogenesis-
dc.subject.meshMale-
dc.subject.meshMelanoma-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshPrognosis-
dc.subject.meshSentinel Lymph Node Biopsy-
dc.subject.meshSkin Neoplasms-
dc.subject.meshTomography, Emission-Computed-
dc.subject.meshTumor Markers, Biological-
dc.subject.meshYoung Adult-
dc.titlePredicting outcome in melanoma: where are we now?en
dc.typeArticleen
dc.contributor.departmentDepartment of Dermatology, Beaumont Hospital, Beaumont, Dublin, Ireland. lorrainejenn@gmail.comen
dc.identifier.journalThe British journal of dermatologyen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.